Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Chang, Pei Ching ^a   Wang, Tao Yeuan ^b,c   Chang, Yi Ting ^a   Chu, Cheng Ying ^d   Lee, Chin Ling ^b,c   Hsu, Hung Wei ^a   Zhou, Tyng An ^a   Wu, Zhaoju ^e,f   Kim, Randie H ^g   Desai, Sonal J ^f   Liu, Shangqin ^h   Kung, Hsing Jien ^d,e,i  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

ⁱ NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ANDROGEN; AUTOPHAGY PROTEIN 5; BECLIN 1; CHLOROQUINE; CHROMOGRANIN A; ETOPOSIDE; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; ATG5 GENE; AUTOPHAGY; BECLIN 1 GENE; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; LC3 GENE; MALE; NEUROENDOCRINE DIFFERENTIATION; ONCOGENE; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REST GENE; SIGNAL TRANSDUCTION; UPREGULATION;

ADENYLATE KINASE; ANDROGENS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHLOROQUINE; CYTOPROTECTION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84895832199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088556     Document Type: Article

References (63)

1. Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41: 834-845. (Pubitemid 40467547)
2. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1-17.
3. Marcu M, Radu E, Sajin M (2010) Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance. Rom J Morphol Embryol 51: 7-12.
4. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, et al. (2009) Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 16: 37-44.
5. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45: 586-592; discussion 592.
6. Jiborn T, Bjartell A, Abrahamsson PA (1998) Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51: 585-589. (Pubitemid 28186211)
7. Yuan TC, Veeramani S, Lin MF (2007) Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14: 531-547. (Pubitemid 350074046)
8. Amorino GP, Parsons SJ (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14: 287-300. (Pubitemid 40221058)
9. Deeble PD, Cox ME, Frierson HF, Jr., Sikes RA, Palmer JB, et al. (2007) Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67: 3663-3672. (Pubitemid 46762151)
10. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, et al. (1999) Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162: 1800-1805. (Pubitemid 29474732)
11. Deeble PD, Murphy DJ, Parsons SJ, Cox ME (2001) Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 8471-8482. (Pubitemid 33108606)
12. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133. (Pubitemid 29446967)
13. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, et al. (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187. (Pubitemid 29422316)
14. Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164: 722-725. (Pubitemid 30637610)
15. Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21.
16. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113.
17. Spiotto MT, Chung TD (2000) STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42: 186-195. (Pubitemid 30080417)
18. Qiu Y, Robinson D, Pretlow TG, Kung HJ (1998) Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 95: 3644-3649.
19. Delk NA, Farach-Carson MC (2012) Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy 8: 650-663.
20. Tsukada M, Ohsumi Y (1993) Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett 333: 169-174. (Pubitemid 23306962)
21. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
22. Holmes D (2011) PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 10: 563-564.
23. Arvisais E, Hou X, Wyatt TA, Shirasuna K, Bollwein H, et al. (2010) Prostaglandin F2alpha represses IGF-I-stimulated IRS1/phosphatidylinositol-3- kinase/AKT signaling in the corpus luteum: role of ERK and P70 ribosomal S6 kinase. Mol Endocrinol 24: 632-643.
24. Zhao Y, Chen H, Shang Z, Jiao B, Yuan B, et al. (2012) SD118-xanthocillin X (1), a novel marine agent extracted from Penicillium commune, induces autophagy through the inhibition of the MEK/ERK pathway. Mar Drugs 10: 1345-1359.
25. Jaber N, Dou Z, Chen JS, Catanzaro J, Jiang YP, et al. (2012) Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc Natl Acad Sci U S A 109: 2003-2008.
26. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, et al. (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9: 218-224. (Pubitemid 46420865)
27. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, et al. (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126: 121-134. (Pubitemid 44040988)
28. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, et al. (2009) Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 8: 1571-1576.
29. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, et al. (2008) Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10: 676-687. (Pubitemid 351772933)
30. Chen N, Karantza V (2011) Autophagy as a therapeutic target in cancer. Cancer Biol Ther 11: 157-168.
31. Xi H, Barredo JC, Merchan JR, Lampidis TJ (2013) Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKbeta leading to autophagy. Biochem Pharmacol 85: 1463-1477.
32. Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, et al. (2012) Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell 48: 667-680.
33. Chen ZF, Paquette AJ, Anderson DJ (1998) NRSF/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis. Nat Genet 20: 136-142. (Pubitemid 28455445)
34. Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, et al. (1995) REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 80: 949-957.
35. Schoenherr CJ, Anderson DJ (1995) Silencing is golden: negative regulation in the control of neuronal gene transcription. Curr Opin Neurobiol 5: 566-571.
36. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G (2005) REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121: 645-657. (Pubitemid 40720016)
37. Ooi L, Wood IC (2007) Chromatin crosstalk in development and disease: lessons from REST. Nat Rev Genet 8: 544-554. (Pubitemid 46955208)
38. Lietz M, Hohl M, Thiel G (2003) RE-1 silencing transcription factor (REST) regulates human synaptophysin gene transcription through an intronic sequence-specific DNA-binding site. Eur J Biochem 270: 2-9. (Pubitemid 36056932)
39. Tawadros T, Martin D, Abderrahmani A, Leisinger HJ, Waeber G, et al. (2005) IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation. Cell Signal 17: 929-939. (Pubitemid 40719114)
40. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, et al. (2013) REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res.
41. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, et al. (2010) Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer 1: 40-49.
42. Chin TY, Kao CH, Wang HY, Huang WP, Ma KH, et al. (2010) Inhibition of the mammalian target of rapamycin promotes cyclic AMP-induced differentiation of NG108-15 cells. Autophagy 6: 1139-1156.
43. Vazquez P, Arroba AI, Cecconi F, de la Rosa EJ, Boya P, et al. (2012) Atg5 and Ambra1 differentially modulate neurogenesis in neural stem cells. Autophagy 8: 187-199.
44. Wang C, Liang CC, Bian ZC, Zhu Y, Guan JL (2013) FIP200 is required for maintenance and differentiation of postnatal neural stem cells. Nat Neurosci 16: 532-542.
45. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, et al. (2005) A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 65: 5263-5271. (Pubitemid 40827337)
46. Mizushima N, Levine B (2010) Autophagy in mammalian development and differentiation. Nat Cell Biol 12: 823-830.
47. Schaeffer V, Goedert M (2012) Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy. Autophagy 8: 1686-1687.
48. Chhipa RR, Wu Y, Ip C (2011) AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cell Signal 23: 1466-1472.
49. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6: 322-329.
50. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, et al. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112: 1809-1820. (Pubitemid 38063704)
51. Li M, Jiang X, Liu D, Na Y, Gao GF, et al. (2008) Autophagy protects LNCaP cells under androgen deprivation conditions. Autophagy 4: 54-60.
52. Boutin B, Tajeddine N, Vandersmissen P, Zanou N, Van Schoor M, et al. (2013) Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. Prostate 73: 1090-1102.
53. Xie S, Lin HK, Ni J, Yang L, Wang L, et al. (2004) Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate 60: 61-67. (Pubitemid 38669230)
54. Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, et al. (2012) Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int J Cancer 131: 582-590.
55. Wu C, Huang J (2007) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282: 3571-3583. (Pubitemid 47084471)
56. Zeng M, Zhou JN (2008) Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. Cell Signal 20: 659-665.
57. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, et al. (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688-2697. (Pubitemid 44923666)
58. Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58: 1953-1960.
59. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, et al. (2006) Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55 Suppl 2: S48-54. (Pubitemid 44927032)
60. White JP, Puppa MJ, Gao S, Sato S, Welle SL, et al. (2013) Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab 304: E1042-1052.
61. Chhipa RR, Wu Y, Mohler JL, Ip C (2010) Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal 22: 1554-1561.
62. Park HU, Suy S, Danner M, Dailey V, Zhang Y, et al. (2009) AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8: 733-741.
63. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, et al. (2012) From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 227: 286-297.